Nuvectis Pharma, Inc. (NVCT) vs OmniAb, Inc. (OABI)

Nuvectis Pharma, Inc. and OmniAb, Inc. are both Biotechnology companies. Nuvectis Pharma, Inc. and OmniAb, Inc. are of similar size ($706.1M and $697.9M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −115.1%) and the higher return on invested capital (0.00% vs −14.5%). Across the 12 metrics below, OmniAb, Inc. leads on 7 and Nuvectis Pharma, Inc. on 5.

Valuation

Metric NVCT OABI Biotechnology median
P/E n/m n/m 7.88
P/S n/m 15.44 11.47
P/B 52.27 2.28 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 14.09 10.73
Earnings yield (6.48%) (7.81%) (28.84%)
Free cash flow yield (4.11%) (3.06%) (23.03%)

Profitability

Metric NVCT OABI Biotechnology median
Gross margin — 98.28% 65.16%
Operating margin 0.00% (125.78%) 0.00%
Net margin 0.00% (115.12%) 0.00%
Free cash flow margin 0.00% (47.17%) 0.00%
Return on equity (233.30%) (16.95%) (57.72%)
Return on assets (122.61%) (15.11%) (49.22%)
Return on invested capital 0.00% (14.52%) 0.00%

Growth

Metric NVCT OABI Biotechnology median
Revenue growth (TTM) — 67.01% 5.64%
EPS growth (last fiscal year) (18.92%) 6.56% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric NVCT OABI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.68 4.80 4.73
Net debt to EBITDA 1.15 1.12 0.96

Dividend

Metric NVCT OABI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric NVCT OABI Biotechnology median
Market cap 706.09m 697.87m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack